1.	Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CPO44/06/FCNS, NCT00589823
2.	Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years Phase: No phase specified Type: Supportive care Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: FT-1301-401-DE, NCT00994760
3.	Instanyl® Non-Interventional Study Phase: No phase specified Type: Supportive care Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: FT-1301-034-SP, NCT01045603